



Sartorius Group  
First-Half Financial Report from January to June 2017

2017

## Key Figures for the First Half of 2017

In millions of € unless otherwise specified

	Group			Bioprocess Solutions			Lab Products & Services		
	6-mo. 2017	6-mo. 2016	Δ in % reported	6-mo. 2017	6-mo. 2016	Δ in % reported	6-mo. 2017	6-mo. 2016	Δ in % reported
<b>Sales Revenue and Order Intake</b>									
Sales revenue	704.1	625.4	12.6	510.9	469.8	8.8	193.2	155.7	24.1
Order intake	741.9	677.6	9.5	546.9	519.2	5.3	195.0	158.4	23.1
<b>Result</b>									
EBITDA <sup>1</sup>	174.5	153.4	13.8	140.8	128.1	10.0	33.7	25.3	33.1
EBITDA margin <sup>1</sup> in %	24.8	24.5		27.6	27.3		17.5	16.3	
Net result <sup>2</sup>	70.9	62.4	13.6						
<b>Financial Data per Share</b>									
Earnings per ord. share <sup>2</sup> in €	1.03	0.91	13.7						
Earnings per pref. share <sup>2</sup> in €	1.04	0.92	13.6						

30.06.2017 31.12.2016

<b>Balance Sheet   Financials</b>	
Balance sheet total	2,291.7
Equity	747.2
Equity ratio in %	32.6
Net debt	919.8
Net debt   underlying EBITDA	2.7

## Key Figures for the Second Quarter of 2017<sup>3</sup>

In millions of € unless otherwise specified

	Group			Bioprocess Solutions			Lab Products & Services		
	Q2 2017	Q2 2016	Δ in % reported	Q2 2017	Q2 2016	Δ in % reported	Q2 2017	Q2 2016	Δ in % reported
<b>Sales Revenue and Order Intake</b>									
Sales revenue	361.0	323.5	11.6	259.8	242.8	7.0	101.2	80.7	25.4
Order intake	365.0	347.5	5.0	263.4	265.0	-0.6	101.6	82.5	23.2
<b>Result</b>									
EBITDA <sup>1</sup>	89.9	81.1	10.9	72.5	67.1	8.0	17.5	14.0	25.0
EBITDA margin <sup>1</sup> in %	24.9	25.1		27.9	27.6		17.3	17.3	
Net result <sup>2</sup>	36.5	33.1	10.1						
<b>Financial Data per Share</b>									
Earnings per ord. share <sup>2</sup> in €	0.53	0.48	10.1						
Earnings per pref. share <sup>2</sup> in €	0.53	0.48	10.1						

<sup>1</sup> Excluding extraordinary items

<sup>2</sup> After non-controlling interest, adjusted for extraordinary items as well as non-cash amortization, and based on the normalized financial result as well as the corresponding tax effects for each of these items

<sup>3</sup> Figures are not audited or reviewed

# Macroeconomic Environment and Sector Conditions

The sectors in which the Sartorius Group is active differ in their dependence on the economy. The Bioprocess Solutions Division, for instance, operates in an environment that is largely independent of economic fluctuations. The Lab Products & Services Division, in contrast, conducts its business activities also in sectors that are more strongly affected by economic factors.

## Global Economy Recorded Slight Growth Acceleration

According to the most recent data, first-quarter economic growth in the OECD countries in 2017 was up 2.0%, slightly above the level of the prior-year quarter of 1.7%.

The world's largest economy, the USA, grew at a somewhat lower rate than expected at the beginning of the year, 1.9% (previous year +1.6%), amid moderate consumer spending. During the further course of the year, stronger growth dynamics are anticipated in view of the robust U.S. labor market, among other factors.

Despite the uncertainties surrounding the planned exit of the U.K. from the European Union, the euro zone reported overall robust development, gaining 1.7% (previous year +1.7%), which was especially driven by strong demand of private households as well as by exports.

Asia proved to be a key growth driver yet again. China's gross domestic product thus rose by 6.9% (previous year +6.7%) due to higher government-led investments, among other reasons. Growth of the economy in India slowed as a result of the country's currency exchange initiative, from 8.7% in the year-earlier quarter to 6.2%. However, it continued to remain at a high level on an international comparison.

Sources: OECD: Quarterly National Accounts, May 2017; Reuters, April 2017.

## Continued Positive Sector Development

Sartorius generates the majority of its business with customers from the biopharmaceutical and pharmaceutical industries. In addition, Sartorius serves customers from public research institutes, the chemical industry and the food sector. Accordingly, the trends in these specific sectors considerably influence the business development of Sartorius.

The international market research institute IMS Health estimates that the global pharmaceutical market has grown annually by around 6% on average over the past five years. The main growth drivers were the availability of innovative new medications, improved access to healthcare – in part through the expansion of state healthcare systems – besides the continuously growing and aging world population.

The market for medications manufactured using biotech methods has been expanding overproportionately for many years within the global pharmaceutical market. This is primarily attributable to a high number of new drug approvals and additional market penetration by existing biologics. Overall, the share of sales revenue generated by medications manufactured using biotech methods relative to the total pharmaceuticals market rose from around 20% in 2012 to approximately 25% in 2016.

Biosimilars, or biological medications nearly identical to original products, have played only a minor role to date in the growth of the biotechnology market. However, the industry has recently made significant progress in the important U.S. market, which develops in a somewhat delayed manner compared to the biosimilars markets in Europe and Asia. So far, five biosimilars have been approved by the FDA, the U.S. health authority, following the first market authorization of a biosimilar in 2015 based on an abbreviated approval procedure.

Demand for laboratory instruments and consumables is primarily generated by the biopharmaceutical and pharmaceutical industries, public research institutes and the chemical and food sectors.

According to data provided by Frost & Sullivan, the global laboratory market grew by about 2.4% in 2016. In the face of moderate economic growth and uncertainty surrounding the British referendum against EU membership, Europe recorded growth of merely 1.5%. The largest market for laboratory products, the USA,

expanded at a rate of 2.5%. Significant growth was once again reported in Asian countries, such as China and India, in which the laboratory market enjoyed above-average expansion of 7.8% (China) and 8.4% (India).

Sources: IMS Health: Outlook for Global Medicines through 2021, December 2016; EvaluatePharma: World Preview 2017, Outlook to 2022, June 2017; [www.biologicsblog.com](http://www.biologicsblog.com), May 19, 2017; Frost & Sullivan: 2017 Spring Mid-year Report; May 2017.

# Group Business Development

- Double-digit growth in sales and profit
- Lab Products & Services develops highly dynamically through organic growth and expansion of its portfolio
- Robust development of Bioprocess Solutions in light of normalized market growth
- Forecast for the full year of 2017 confirmed

## Product Portfolio Expanded Through Acquisitions

In the first half of 2017, Sartorius added further innovative and complementary technologies to its product array through two acquisitions. The Lab Products & Services Division significantly expanded its portfolio in bioanalytics through the acquisition of Essen BioScience and thus has further strengthened its position with biopharmaceutical customers and in public research. Moreover, the Bioprocess Solutions Division expanded its comprehensive offering of single-use solutions and equipment through the acquisition of the data analytics specialist Umetrics.

For further information about these acquisitions, please see pp. 8 and 9.

## Sartorius Achieves Double-Digit Sales Growth in the First Half

In the first half of 2017, the Sartorius Group continued to grow dynamically at double-digit rates. In light of the strong organic growth of both of its divisions and the acquisitions of Essen BioScience and Umetrics, the company's sales revenue rose 11.5% in constant currencies from €625.4 million to €704.1 million; the reported increase was 12.6%.


### Sales revenue and order intake

in millions of €	6-mo. 2017	6-mo. 2016	Δ in % reported	Δ in % cc <sup>1</sup>
Sales revenue	<b>704.1</b>	625.4	12.6	11.5
Order intake	<b>741.9</b>	677.6	9.5	8.4

<sup>1</sup> In constant currencies

All regions contributed to growth of the Sartorius Group in the first half of 2017. Sales revenue in the Asia | Pacific region, which accounted for around 24% of total Group sales, showed the highest momentum, achieving growth of 34.8% to €172.2 million (reported +37.7% compared with €125.1 million a year ago).

**Sales revenue and growth<sup>1</sup> by region<sup>2</sup>**  
in millions of € unless otherwise specified



<sup>1</sup> In constant currencies

<sup>2</sup> Acc. to customers' location

The EMEA region, representing around 43% of total Group sales, recorded a gain of 5.9% to €302.9 million against a high revenue base in the year-earlier period (reported +5.1%, compared with €288.1 million).

Sales revenue in the Americas region, which accounted for around 33% of total sales, was €229.0 million, up 4.8% from a year ago (reported +7.9% compared with €212.3 million in 2016).

All changes given for the regional development are in constant currencies, unless otherwise specified.

## Underlying EBITDA Increases Overproportionately

The Sartorius Group uses underlying EBITDA (earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items) as the key profitability indicator.

The Sartorius Group increased its earnings overproportionately yet again in the first half of 2017 relative to sales. Driven by economies of scale, underlying EBITDA rose 13.8% from €153.4 million to €174.5 million. The respective EBITDA margin climbed from 24.5% in the year-earlier period to 24.8%.

Underlying EBITDA and EBITDA margin Group			
in millions of €	6-mo. 2017	6-mo. 2016	Δ in %
Underlying EBITDA	174.5	153.4	13.8
Underlying EBITDA margin	24.8	24.5	

Consolidated EBIT, including extraordinary items of -€12.7 million (H1 2016: -€9.9 million), depreciation and amortization, amounted to €113.9 million compared with €109.9 million in the previous year. Extraordinary items were primarily related to various cross-divisional projects and expenses in connection with the Group's most recent acquisitions. Due to an acquisition-driven increase of amortization, the consolidated EBIT margin was 16.2%, up from 17.6% a year ago.

The financial result was -€9.0 million in the first half of 2017, relative to -€3.9 million for the prior-year period. This change is essentially attributable to valuation effects related to foreign currency liabilities and hedging instruments and to a smaller extent to higher interest expenses due to acquisitions.

Net profit for the first six months of 2017 totaled €74.5 million relative to €74.2 million in the comparable period. Net profit after non-controlling interest stood at €51.8 million relative to €53.4 million in the first half of 2016, with non-controlling interest accounting for €22.7 million (H1 2016: €20.8 million).

## Relevant Net Profit Rises Significantly

The relevant net profit attributable to the shareholders of Sartorius AG rose by 13.6% from €62.4 million to €70.9 million. This profit figure is calculated by adjusting for extraordinary items and eliminating non-cash amortization, and is based on the normalized financial result as well as the corresponding tax effects for each of these items. Underlying earnings per ordinary share totaled €1.03 (H1 2016: €0.91) and €1.04 per preference share (H1 2016: €0.92).

in millions of €	6-mo. 2017	6-mo. 2016
EBIT	113.9	109.9
Extraordinary effects	12.7	9.9
Amortization	17.0	8.5
Normalized financial result <sup>1</sup>	-8.3	-6.8
Normalized income tax (2017: 29%   2016: 30%) <sup>2</sup>	-39.2	-36.4
<b>Underlying net result after tax</b>	<b>96.1</b>	<b>85.0</b>
Non-controlling interest	-25.1	-22.6
<b>Underlying earnings after taxes and non-controlling interest</b>	<b>70.9</b>	<b>62.4</b>
Underlying earnings per share		
per ordinary share in €	1.03	0.91
per preference share in €	1.04	0.92

<sup>1</sup> Financial result excluding fair value adjustments of hedging instruments and currency effects relating to financing activities

<sup>2</sup> Underlying income tax, based on the underlying profit before tax and non-cash amortization

## Operating Cash Flow Increases

In the first six months of the current fiscal year, the Sartorius Group reported a net cash flow from operating activities of €54.3 million relative to €43.1 million a year ago. Besides reflecting an increase in earnings, this development was influenced by lower tax payments than in the previous year and by a predominantly growth-related increase in funds allocated to working capital.

Net cash flow from investing activities was -€79.5 million, above the year-earlier figure of -€69.0 million, as planned. Capital expenditures in the reporting period were related to, inter alia, the expansion of production capacity at our site in Yauco, Puerto Rico, and the consolidation and expansion of Group headquarters in Goettingen, Germany. The ratio of capital expenditures relative to sales in the first half of 2017 was 12.9% (previous year: 11.5%)

Cash outflows associated with acquisitions of €362.6 million in the first half of 2017 were related to the purchase of Essen BioScience and Umetrics. The cash outflow of €79.1 million in the year-earlier period reflects the acquisition of IntelliCyt. On the whole, net cash flow from investing activities and acquisitions was -€442.1 million relative to the prior-year figure of -€148.1 million.

### Key Balance Sheet and Financial Indicators Remain at Good Levels

The balance sheet total for the Sartorius Group stood at €2,291.7 million in the period ended June 30, 2017, compared to €1,753.0 million as of December 31, 2016. This increase is mainly due to the acquisitions of Essen BioScience and Umetrics.

The Group's equity rose slightly from €736.8 million to €747.2 million between December 31, 2016, and the reporting date. The equity ratio continued to remain at a comfortable level at 32.6% (December 31, 2016: 42.0%).

Gross debt increased from €547.9 million as of December 31, 2016, to €992.3 million as of June 30, 2017, primarily due to the acquisitions mentioned above. Net debt was €919.8 million relative to €485.9 million as of December 31, 2016.

In this context, the ratio of net debt to underlying EBITDA based on the past 12 months rose from 1.5 at year-end 2016, to 2.7 as of June 20, 2017.

### Number of Employees Increases

As of June 30, 2017, the Sartorius Group employed a total of 7,364 people worldwide. Compared with December 31, 2016, head count thus rose by 453 or around 7%. This figure includes 208 staff from the acquisitions of Essen BioScience and Umetrics. From a geographical perspective, personnel increased predominantly in the Americas region, by 19%. The number of employees in the EMEA region rose in the reporting period by around 5% to 5,082. In Asia | Pacific, Sartorius employed 1,106 people as of the end of the reporting period (December 31, 2016: 1,069 staff).

# Business Development of the Divisions

## Bioprocess Solutions: Portfolio Expanded by the Acquisition of Data Analytics Specialist Umetrics

In April 2017, Sartorius expanded the portfolio of its Bioprocess Solutions Division through the acquisition of the Swedish company Umetrics. This company is a leading specialist in data analytics software for modeling and optimizing biopharmaceutical development and manufacturing processes, and has already been cooperating with Sartorius for around five years. For the full year of 2017, Umetrics plans to generate sales revenue of around U.S. \$15 million, approximately three-fourths of which will be consolidated by the Bioprocess Solutions Division this year.

## Robust Performance Given Normalized Market Growth

In the period under review, the dynamics of the bioprocess market returned to normal rates, as expected, after two years of extraordinarily strong growth. The Bioprocess Solutions Division thus recorded an increase in first-half sales revenue of 8.0% in constant currencies to €510.9 million (reported +8.8%). In particular, development of sales in the Americas region was influenced by relatively soft customer demand and limited delivery capacity for cell culture media. Consolidation of kSep acquired in July 2016 and of Umetrics contributed nearly 1 percentage point of non-organic growth.

The division's business development in the first half was quite different in the regions. The Asia|Pacific region achieved the highest gains, with sales revenue up 44.4% due to the delivery of some large equipment orders, among other reasons. By contrast, first-half business in the Americas was slightly below the strong previous year's level (-2.6%) due to the factors mentioned above. In the EMEA region, sales increased by 2.2% against a very high revenue base in the first half of 2016.

### Bioprocess Solutions

in millions of €	6-mo. 2017	6-mo. 2016	Δ in % reported	Δ in % const. fx
Sales revenue	<b>510.9</b>	469.8	8.8	8.0
- EMEA <sup>1</sup>	<b>209.4</b>	207.2	1.0	2.2
- Americas <sup>1</sup>	<b>181.3</b>	181.1	0.1	-2.6
- Asia   Pacific <sup>1</sup>	<b>120.3</b>	81.5	47.6	44.4
Order intake	<b>546.9</b>	519.2	5.3	4.4

<sup>1</sup> Acc. to customers' location

The division's first-half order intake rose by 4.4% compared with a very strong prior-year base, which was influenced by some larger equipment orders.

Underlying EBITDA of the Bioprocess Solutions Division increased by 10.0% from €128.1 million to €140.8 million. Its respective margin rose from 27.3% to 27.6%, especially due to economies of scale.

### Underlying EBITDA and EBITDA margin Bioprocess Solutions

in millions of €	6-mo. 2017	6-mo. 2016	Δ in %
Underlying EBITDA	<b>140.8</b>	128.1	10.0
Underlying EBITDA margin in %	<b>27.6</b>	27.3	



## Lab Products & Services: Bioanalytics Portfolio Considerably Expanded

The Lab Products & Services Division significantly expanded its offering of innovative technologies for drug research in the area of bioanalytics with the purchase of U.S.-based Essen BioScience Inc. in March 2017 after acquiring IntelliCyt and ViroCyt in the summer of 2016. Essen's real-time live-cell imaging and analysis systems are an excellent complementary fit with IntelliCyt's products, offering additional growth potential for Lab Products & Services. Essen BioScience is expected to generate sales revenue of around U.S. \$60 million for the full year of 2017, about three-fourths of which will be consolidated by the Lab Products & Services Division this year.

### Continued Positive Business Development

In the first half of 2017, the Lab Products & Services Division increased its sales revenue significantly by 22.1% in constant currencies to €193.2 million (reported +24.1%). The division reported organic growth of around 7% due to strong demand in all regions and all product areas. The portfolio expansion in the area of bioanalytics contributed around 15 percentage points to growth.

#### Lab Products & Services

in millions of €	6-mo. 2017	6-mo. 2016	Δ in % reported	Δ in % const. fx
Sales revenue	<b>193.2</b>	155.7	24.1	22.1
- EMEA <sup>1</sup>	<b>93.5</b>	80.8	15.7	15.1
- Americas <sup>1</sup>	<b>47.7</b>	31.2	53.0	47.5
- Asia   Pacific <sup>1</sup>	<b>52.0</b>	43.6	19.2	17.2
Order intake	<b>195.0</b>	158.4	23.1	21.1

<sup>1</sup> Acc. to customers' location

Underlying EBITDA of the Lab Products & Services Division rose sharply in the first half of 2017 by 33.1% from €25.3 million to €33.7 million. This increase was driven by economies of scale related to strong organic growth and acquisitions. The division's underlying EBITDA earnings margin improved from 16.3% a year ago to 17.5%.

Underlying EBITDA and EBITDA margin Lab Products & Services			
in millions of €	6-mo. 2017	6-mo. 2016	Δ in %
Underlying EBITDA	<b>33.7</b>	25.3	33.1
Underlying EBITDA margin in %	<b>17.5</b>	16.3	

# Opportunity and Risk Report

The opportunities and risk situation of the Sartorius Group has not materially changed since the publication of its 2016 Annual Report. For this reason, please refer to the detailed description of the opportunities and risks on pp. 52 et seq., as well as the risk management system on pp. 65 et seq., for the Sartorius Group in the 2016 Annual Report.

## Forecast Report

### Macroeconomic Outlook Slightly Improved

According to the most recent forecast issued by the International Monetary Fund, IMF, expansion of the global economy in 2017 is expected to progress slightly better at a rate of 3.5% compared with 3.4% projected at the beginning of the year.

For the U.S. market, the IMF continues to predict that economic activity will gain momentum at a rate of 2.3% compared with 1.6% a year ago. Key growth drivers are an end to inventory reductions and a rebound in investment activity.

The IMF also slightly raised its growth expectations for the euro zone since the beginning of the year from 1.5% to 1.7% due to continuing expansive fiscal policy and the positive effects of the pickup in the U.S. economy. In the U.K., the effects of its planned withdrawal from the European Union are likely to be lower than expected over the short term. For this reason, the IMF estimates that the U.K. economy will grow by 2.0%.

Experts project that the Asian economic area will expand by 6.4%, unchanged from the prior year. Supported by government investments, China's economy is likewise expected to grow by 6.6%. The IMF estimates that the development of India's economy in the current year will be impacted by its currency exchange initiative. Accordingly, the IMF revised its most recent forecast to +7.2% for 2017.

Sources: International Monetary Fund, World Economic Outlook, April 2017.

### Continued Positive Sector Environment

The trends described on pages 61–63 of our 2016 Annual Report have remained unchanged with respect to their impacts on the development of the Sartorius Group.

Most recent estimates project that the global pharmaceutical market will grow at a compound annual growth rate of 4% to 7% during the period of 2016 to 2021. For the biopharma subsegment, market observers continue to expect overproportionate annual growth of around 9% on average. This growth will be driven largely by the increasing penetration of biopharmaceuticals already approved and an expansion of their indications, as well as by strong research and development pipelines.

Based on Frost & Sullivan estimates, global demand for laboratory products is forecasted to remain stable. Therefore, growth of around 2.8% is projected for 2017. While the markets in the USA and Europe are likely to expand moderately at rates of 3.2% and 1.9%, respectively, market observers expect the highest growth rates in Asian countries, for instance, 7.6% for China and 8.6% for India.

Sources: IMS Health: Outlook for Global Medicines through 2021, December 2016; Frost & Sullivan; Frost & Sullivan: 2017 Mid-year Report; May 2017; EvaluatePharma: World Preview 2017, Outlook to 2022, June 2017.

### Guidance for Fiscal 2017 Confirmed

Management confirms its forecast for the full year of 2017.

### Group

Based on constant currencies, management maintains its projection that Group sales revenue will grow by about 12% to 16%. The Group's underlying EBITDA margin is expected to increase by slightly more than half a percentage point over the prior-year figure of 25.0%.

For 2017, Sartorius continues to plan on investing about 12% to 15% of sales revenue. Its investing activities remain focused on the expansion of its site in Yauco, Puerto Rico, for the manufacture of single-use bags and filters, as well as on consolidation and extension of Group headquarters in Goettingen, Germany.

Regarding its financial position, Sartorius expects that in light of its most recent acquisitions, its ratio of net debt to underlying EBITDA by the end of the current fiscal year will be around 2.4. Any further potential acquisitions are not reflected in this guidance.

## Divisions

For the Bioprocess Solutions Division, management continues to anticipate that sales will grow by about 9% to 13%, which includes a good one percentage point of non-organic growth to be contributed by the acquired companies, kSep and Umetrics. With regard to delivery capacities for cell culture media, management assumes that the situation will normalize in the third quarter of 2017. The division's underlying EBITDA margin remains projected to rise by about half a percentage point over the prior-year figure of 28.0%.

For the Lab Products & Services Division, management continues to project that, assuming an overall stable economic environment, sales will increase by about 20% to 24%. This includes non-organic growth of around 17 percentage points to be contributed by the companies acquired, IntelliCyt, ViroCyt and Essen BioScience. The division's underlying EBITDA margin is expected rise by nearly two percentage points compared with the prior-year figure of 16.0%.

All forecasts are based on constant currencies.

## Report on Material Events

No material events occurred after June 30, 2017.

## Condensed Interim Financial Statements

### Statement of Profit or Loss | Statement of Comprehensive Income

	2nd quarter <sup>1)</sup> 2017 € in mn	2nd quarter <sup>1)</sup> 2016 € in mn	6-month 2017 € in mn	6-month 2016 € in mn
Sales revenue	361.0	323.5	704.1	625.4
Cost of sales	-184.8	-167.3	-357.0	-320.4
<b>Gross profit on sales</b>	<b>176.2</b>	<b>156.2</b>	<b>347.1</b>	<b>305.1</b>
Selling and distribution costs	-76.0	-62.3	-146.0	-123.1
Research and development expenses	-18.5	-15.2	-35.0	-29.6
General administrative expenses	-19.8	-18.5	-41.3	-36.2
Other operating income and expenses <sup>2)</sup>	-5.0	-0.3	-11.0	-6.3
<b>Earnings before interest and taxes (EBIT)</b>	<b>56.8</b>	<b>60.0</b>	<b>113.9</b>	<b>109.9</b>
Financial income	1.6	3.6	2.8	8.1
Financial expenses	-6.9	-6.7	-11.7	-12.0
<b>Financial result</b>	<b>-5.3</b>	<b>-3.1</b>	<b>-9.0</b>	<b>-3.9</b>
<b>Profit before tax</b>	<b>51.5</b>	<b>56.9</b>	<b>104.9</b>	<b>106.0</b>
Income taxes	-14.9	-17.1	-30.4	-31.8
<b>Net profit for the period</b>	<b>36.6</b>	<b>39.8</b>	<b>74.5</b>	<b>74.2</b>
Attributable to:				
Shareholders of Sartorius AG	25.2	29.1	51.8	53.4
Non-controlling interest	11.4	10.7	22.7	20.8
<b>Earnings per ordinary share (€) (basic)</b>	<b>0.37</b>	<b>0.43</b>	<b>0.75</b>	<b>0.78</b>
<b>Earnings per preference share (€) (basic)</b>	<b>0.37</b>	<b>0.43</b>	<b>0.76</b>	<b>0.79</b>
<b>Earnings per ordinary share (€) (diluted)</b>	<b>0.37</b>	<b>0.43</b>	<b>0.75</b>	<b>0.78</b>
<b>Earnings per preference share (€) (diluted)</b>	<b>0.37</b>	<b>0.43</b>	<b>0.76</b>	<b>0.79</b>

<sup>1)</sup> The 2nd quarter figures were not included in the auditors' review.

<sup>2)</sup> The item "Other operating income and expenses" includes extraordinary expenses for Group projects and acquisition and integration costs of €12.7 million for the six-month period of 2017 (6-mo. 2016: €9.9 million).

## Statement of Comprehensive Income

	2nd quarter <sup>1)</sup> 2017 € in mn	2nd quarter <sup>1)</sup> 2016 € in mn	6-month 2017 € in mn	6-month 2016 € in mn
<b>Net profit for the period</b>	<b>36.6</b>	<b>39.8</b>	<b>74.5</b>	<b>74.2</b>
Cash flow hedges	19.1	-0.3	24.8	0.5
- of which effective portion of the change in fair value	18.3	-0.8	22.7	-1.4
- of which reclassified to profit or loss	0.8	0.5	2.1	1.9
Income tax on cash flow hedges	-5.7	0.1	-7.4	-0.2
Net investment in a foreign operation	-27.3	-2.1	-25.6	0.2
Income tax on net investment in a foreign operation	2.7	0.5	2.2	-0.2
Currency translation differences	-19.5	3.1	-18.1	-13.7
<b>Items that may be reclassified in the profit or loss statement, net of tax</b>	<b>-30.7</b>	<b>1.4</b>	<b>-24.2</b>	<b>-13.2</b>
Remeasurements of the net defined benefit liability	2.0	-7.4	2.0	-7.4
Income tax on items that will not be reclassified in the profit or loss statement	-0.5	2.2	-0.5	2.2
<b>Items that will not be reclassified in the profit or loss statement, net of tax</b>	<b>1.5</b>	<b>-5.2</b>	<b>1.5</b>	<b>-5.2</b>
<b>Other comprehensive result after tax</b>	<b>-29.2</b>	<b>-3.8</b>	<b>-22.7</b>	<b>-18.4</b>
<b>Total comprehensive income</b>	<b>7.3</b>	<b>36.0</b>	<b>51.8</b>	<b>55.8</b>
Attributable to:				
Shareholders of Sartorius AG	-1.9	25.2	29.9	38.8
Non-controlling interest	9.3	10.8	21.9	17.0

<sup>1)</sup> The 2nd quarter figures were not included in the auditors' review.

## Statement of Financial Position

	June 30, 2017	December 31, 2016
	€ in mn	€ in mn
<b>Assets</b>		
<b>Non-current assets</b>		
Goodwill	667.6	467.8
Other intangible assets	467.6	267.4
Property, plant and equipment	443.8	394.0
Financial assets	17.7	7.5
Other assets	0.8	0.9
Deferred tax assets	26.8	27.7
	<b>1,624.4</b>	<b>1,165.4</b>
<b>Current assets</b>		
Inventories	241.9	222.2
Trade receivables	271.6	241.2
Other financial assets	27.4	15.0
Current tax assets	16.4	21.6
Other assets	33.0	22.0
Cash and cash equivalents	72.4	62.0
Assets held for sale	4.6	3.6
	<b>667.3</b>	<b>587.6</b>
<b>Total assets</b>	<b>2,291.7</b>	<b>1,753.0</b>
	June 30, 2017	December 31, 2016
	€ in mn	€ in mn
<b>Equity and liabilities</b>		
<b>Equity</b>		
<b>Equity attributable to Sartorius AG shareholders</b>	<b>578.8</b>	<b>579.7</b>
Issued capital	68.4	68.4
Capital reserves	39.1	38.4
Other reserves and retained earnings	471.3	472.9
Non-controlling interest	168.4	157.1
	<b>747.2</b>	<b>736.8</b>
<b>Non-current liabilities</b>		
Pension provisions	62.4	64.1
Other provisions	7.8	7.8
Loans and borrowings	906.3	433.0
Finance lease liabilities	18.2	18.9
Other financial liabilities	67.9	73.7
Deferred tax liabilities	130.7	54.3
	<b>1,193.4</b>	<b>651.8</b>
<b>Current liabilities</b>		
Provisions	17.2	18.1
Trade payables	127.4	120.4
Loans and borrowings	64.9	93.0
Finance lease liabilities	2.8	3.0
Employee benefits	52.3	49.0
Other financial liabilities	22.9	32.3
Current tax liabilities	23.7	23.6
Other liabilities	39.9	25.0
	<b>351.2</b>	<b>364.4</b>
<b>Total equity and liabilities</b>	<b>2,291.7</b>	<b>1,753.0</b>

## Statement of Cash Flows

	6-month 2017 € in mn	6-month 2016 € in mn
Profit before tax	104.9	106.0
Financial result	9.0	3.9
<b>Earnings before interest and taxes (EBIT)</b>	<b>113.9</b>	<b>109.9</b>
Depreciation   amortization of intangible and tangible assets	48.0	33.6
Increase   decrease in provisions	-0.9	1.1
Income taxes paid	-28.7	-32.0
Other non-cash items	1.0	0.7
<b>Gross cash flows from operating activities</b>	<b>133.2</b>	<b>113.3</b>
Increase   decrease in receivables and other assets	-35.6	-51.8
Increase   decrease in inventories	-16.7	-29.8
Increase   decrease in liabilities (without loans and borrowings)	-26.6	11.5
<b>Net cash flow from operating activities</b>	<b>54.3</b>	<b>43.1</b>
Capital expenditures	-79.5	-69.4
Proceeds from the disposal of fixed assets	0.0	0.4
<b>Net cash flow from investing activities</b>	<b>-79.5</b>	<b>-69.0</b>
Payments for acquisitions of consolidated subsidiaries and other business operations, net of cash acquired	-362.6	-79.1
<b>Net cash flow from investing activities, acquisitions and disposals</b>	<b>-442.1</b>	<b>-148.1</b>
Interest received	0.2	2.1
Interest paid and other financial charges	-4.3	-3.6
Dividends paid to:		
- Shareholders of Sartorius AG	-31.1	-25.8
- Non-controlling interest	-10.7	-8.7
<b>Gross cash flows from financing activities</b>	<b>-45.9</b>	<b>-36.0</b>
Loans repaid	-70.8	-2.3
Loans raised	515.0	164.5
<b>Net cash flow from financing activities</b>	<b>398.3</b>	<b>126.3</b>
Net increase   decrease in cash and cash equivalents	10.6	21.3
Cash and cash equivalents at the beginning of the period	62.0	52.8
Net effect of currency translation on cash and cash equivalents	-0.2	2.0
<b>Cash and cash equivalents at the end of the period</b>	<b>72.4</b>	<b>76.0</b>

## Statement of Changes in Equity

€ in millions	Issued capital	Capital reserves	Hedging reserves	Pension reserves	Earnings reserves and retained profits	Difference resulting from currency translation	Equity attributable to Sartorius AG shareholders	Non-controlling interest	Total equity
<b>Balance at January 1, 2016</b>	<b>17.1</b>	<b>88.4</b>	<b>-3.1</b>	<b>-15.1</b>	<b>406.5</b>	<b>24.0</b>	<b>517.7</b>	<b>127.0</b>	<b>644.8</b>
Net profit for the period	0.0	0.0	0.0	0.0	53.4	0.0	53.4	20.8	74.2
Cash flow hedges	0.0	0.0	0.3	0.0	0.0	0.0	0.3	0.3	0.5
Actuarial gains   losses from pension provisions	0.0	0.0	0.0	-6.4	0.0	0.0	-6.4	-1.0	-7.4
Currency translation differences	0.0	0.0	0.0	0.0	0.0	-10.2	-10.2	-3.5	-13.7
Net investment in a foreign operation	0.0	0.0	0.0	0.0	-0.1	0.0	-0.1	0.3	0.2
Income tax on items that are recognized in other comprehensive income	0.0	0.0	-0.1	1.9	0.0	0.0	1.8	0.1	1.9
<b>Other comprehensive result after tax</b>	<b>0.0</b>	<b>0.0</b>	<b>0.2</b>	<b>-4.6</b>	<b>-0.1</b>	<b>-10.2</b>	<b>-14.6</b>	<b>-3.8</b>	<b>-18.4</b>
<b>Total comprehensive income</b>	<b>0.0</b>	<b>0.0</b>	<b>0.2</b>	<b>-4.6</b>	<b>53.3</b>	<b>-10.2</b>	<b>38.8</b>	<b>17.0</b>	<b>55.8</b>
Share-based payment	0.0	0.7	0.0	0.0	0.0	0.0	0.7	0.0	0.7
Dividends	0.0	0.0	0.0	0.0	-25.8	0.0	-25.8	-8.7	-34.5
Capital increase <sup>1)</sup>	51.3	-51.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchase price liability Israel	0.0	0.0	0.0	0.0	-13.4	0.0	-13.4	0.0	-13.4
Other changes in equity	0.0	0.0	0.0	0.5	0.4	0.0	1.0	-0.2	0.8
<b>Balance at June 30, 2016</b>	<b>68.4</b>	<b>37.7</b>	<b>-2.9</b>	<b>-19.2</b>	<b>421.1</b>	<b>13.9</b>	<b>519.0</b>	<b>135.1</b>	<b>654.2</b>

€ in millions	Issued capital	Capital reserves	Hedging reserves	Pension reserves	Earnings reserves and retained profits	Difference resulting from currency translation	Equity attributable to Sartorius AG shareholders	Non-controlling interest	Total equity
<b>Balance at January 1, 2017</b>	<b>68.4</b>	<b>38.4</b>	<b>-7.3</b>	<b>-17.7</b>	<b>473.6</b>	<b>24.3</b>	<b>579.7</b>	<b>157.1</b>	<b>736.8</b>
Net profit for the period	0.0	0.0	0.0	0.0	51.8	0.0	51.8	22.7	74.5
Cash flow hedges	0.0	0.0	19.8	0.0	0.0	0.0	19.8	5.0	24.8
Actuarial gains   losses from pension provisions	0.0	0.0	0.0	1.7	0.0	0.0	1.7	0.3	2.0
Currency translation differences	0.0	0.0	0.0	0.0	0.0	-13.6	-13.6	-4.4	-18.1
Net investment in a foreign operation	0.0	0.0	0.0	0.0	-25.6	0.0	-25.6	0.0	-25.6
Income tax on items that are recognized in other comprehensive income	0.0	0.0	-5.9	-0.4	2.2	0.0	-4.2	-1.6	-5.7
<b>Other comprehensive result after tax</b>	<b>0.0</b>	<b>0.0</b>	<b>13.9</b>	<b>1.3</b>	<b>-23.4</b>	<b>-13.6</b>	<b>-21.9</b>	<b>-0.8</b>	<b>-22.7</b>
<b>Total comprehensive income</b>	<b>0.0</b>	<b>0.0</b>	<b>13.9</b>	<b>1.3</b>	<b>28.4</b>	<b>-13.6</b>	<b>29.9</b>	<b>21.9</b>	<b>51.8</b>
Share-based payment	0.0	0.7	0.0	0.0	0.0	0.0	0.7	0.0	0.7
Dividends	0.0	0.0	0.0	0.0	-31.1	0.0	-31.1	-10.7	-41.8
Other changes in equity	0.0	0.0	0.0	0.0	-0.4	0.0	-0.4	0.1	-0.3
<b>Balance at June 30, 2017</b>	<b>68.4</b>	<b>39.1</b>	<b>6.6</b>	<b>-16.4</b>	<b>470.4</b>	<b>10.7</b>	<b>578.8</b>	<b>168.4</b>	<b>747.2</b>

<sup>1)</sup> In fiscal 2016, capital was increased by the use of retained earnings to perform a stock split.



## Segment Reports

According to IFRS 8, Operating Segments, the identification of reportable operating segments is based on the "management approach"; i.e., the segments are defined analogously to the internal control and reporting structure of an entity. Accordingly, the divisions called Bioprocess Solutions and Lab Products & Services are to be considered operating segments.

"Underlying EBITDA" is the key performance indicator of the operating segments of the Sartorius Group. EBITDA corresponds to earnings before interest (financial result), taxes, depreciation and amortization. "Un-

derlying EBITDA" means EBITDA adjusted for extraordinary items. In this connection, extraordinary items are expenses and income that are of an exceptional or a one-time nature and accordingly distort the sustainable profitability of a segment and, from the Group's perspective, have a material impact on the net worth, financial position and earnings of the Group.

Apart from that, the recognition and measurement methods for the reportable segments conform to the general Group accounting principles.

€ in millions	Sales revenue		Underlying EBITDA	
	6-mo. 2017	6-mo. 2016	6-mo. 2017	6-mo. 2016
Bioprocess Solutions	510.9	469.8	140.8	128.1
Lab Products & Services	193.2	155.7	33.7	25.3
<b>Total continuing operations</b>	<b>704.1</b>	<b>625.4</b>	<b>174.5</b>	<b>153.4</b>
<b>Reconciliation to the profit before tax</b>				
Depreciation and amortization			-48.0	-33.6
Extraordinary items			-12.7	-9.9
<b>Earnings before interest and taxes (EBIT)</b>			<b>113.9</b>	<b>109.9</b>
Financial result			-9.0	-3.9
<b>Profit before tax from continuing operations</b>			<b>104.9</b>	<b>106.0</b>

## Geographical Information

€ in millions	Sales revenue	
	6-mo. 2017	6-mo. 2016
EMEA	302.9	288.1
Americas	229.0	212.3
Asia   Pacific	172.2	125.1
<b>Group</b>	<b>704.1</b>	<b>625.4</b>

# Notes to the Condensed Interim Financial Statements

## 1. General Information

Sartorius AG is a listed joint stock corporation established according to German law and is the highest-level parent company of the Sartorius Group. The corporation is recorded in the German Commercial Register of the District Court of Goettingen (HRB 1970) and is headquartered at Weender Landstrasse 94–108 in Goettingen, Federal Republic of Germany.

The Sartorius Group organizes its business in two divisions: Bioprocess Solutions and Lab Products & Services. With its Bioprocess Solutions Division, Sartorius is a leading international supplier of products and technologies for the manufacture of medications and vaccines on a biological basis, so-called biopharmaceuticals. As part of its total solutions provider strategy, the Bioprocess Solutions Division offers the biopharmaceutical industry a product portfolio that covers nearly all process steps of the industry's manufacture. These products encompass cell culture media for the cultivation of cells, bioreactors of various sizes for cell propagation and different technologies, such as filters and bags for cell harvesting, purification and concentration, all the way to filling.

The Lab Products & Services Division focuses on laboratories in the research and quality assurance sectors of pharmaceutical and biopharmaceutical companies and on academic research institutes. It serves further customers in the chemical and food industries. The division's portfolio covers instruments and consumables that laboratories use, for example, in sample preparation or in other standard applications.

## 2. Significant Accounting Policies

The consolidated annual financial statements of Sartorius AG for the period ended December 31, 2016, were prepared in accordance with the accounting standards of the International Accounting Standards Board (IASB) – the International Financial Reporting Standards (IFRS) – as they are to be applied in the EU. In the present interim financial statements that were prepared in conformance with the requirements of IAS 34 "Interim financial reporting," basically the same accounting and measurement principles were applied on which the past consolidated financial statements of fiscal 2016 were based.

Furthermore, all interpretations of the International Financial Reporting Standards Interpretations Committee (IFRS IC) to be applied effective June 30, 2017, were observed. An explanation of the individual accounting and measurement principles applied is given in the Notes to the Financial Statements of the Group for the year ended December 31, 2016.

A list of the companies included in the scope of consolidation for the Group financial statements is provided in our 2016 Annual Report. In the current fiscal year, the following companies were consolidated for the first time in the reporting period:

- Essen Holdings Inc., USA
- Essen Intermediate Holdings Inc., USA
- Essen Instruments Inc., USA
- Essen BioScience Ltd., UK
- Essen BioScience K.K., Japan
- Sartorius Stedim Data Analytics, Sweden

These are additions from acquisitions; see Section 5 for details.

For calculation of income tax expenses, the provisions of IAS 34.30c) were adopted; i.e., the best estimate of the weighted average annual income tax rate expected for the full financial year, 29%, was applied.

## 3. Use of Judgments and Estimates

In preparing these interim financial statements, management has made judgments, estimates and assumptions, based on their best knowledge of the current and future situation, that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates, however.

The significant judgments and estimates made by management in applying the Group's accounting policies and the key sources of estimation uncertainty have remained the same as those that were applied to the consolidated financial statements for the year ended December 31, 2016.

#### 4. Accounting Rules Applied for the First Time in the Current Fiscal Year

The Group did not yet apply the following new accounting rules as their application was not yet mandatory for the reporting period:

- Annual Improvements to IFRSs – Cycle 2014-2016 (issued in Dec. 2016), Amendments to IFRS 12
- Amendments to IAS 12, Recognition of Deferred Tax Assets for Unrealised Losses
- Amendments to IAS 7, Disclosure Initiative

First-time application of these standards is not expected to have an impact on the presentation of the Group's financial statements. The following amendments are to be applied as of 2018 (IFRS 15, IFRS 9) and 2019 (IFRS 16):

IFRS 15, Revenue from Contracts with Customers, defines a comprehensive framework for determining whether, in which amount and at which point in time revenue is to be recognized. This standard replaces the existing guidance for revenue recognition, including IAS 18, Revenue; IAS 11, Construction contracts; and IFRIC 13, Customer Loyalty Programmes.

The Group is currently conducting a project to analyze the effects of the application of the new standards in the future. At this time, the Group does not expect any material changes regarding the amount and timing of revenue for the major part of the Group's business. However, especially in the case of construction contracts that are currently accounted for under IAS 11, the timing of revenue recognition may change as a result of the new criteria of IFRS 15 for revenue recognition over time.

At the current state of analysis, the Group does not expect full retrospective application of this new standard. Instead, the Group plans to recognize the cumulative effect of applying IFRS 15 at the date of initial application as an adjustment to the opening balance of equity. Furthermore, at initial application, the Group expects to apply IFRS 15 only to contracts that are not considered completed contracts at the date of initial application.

IFRS 9, Financial Instruments, replaces the existing guidelines in IAS 39, Financial instruments: recognition and measurement. IFRS 9 includes revised guidelines for classification and measurement of financial instruments, including a new model of expected credit

losses for the calculation of impairments of financial assets, as well as the new general guidelines for hedge accounting. This standard also adopts the guidance of IAS 39 for recognition and derecognition of financial instruments. The Group is currently conducting a project to analyze the effects of the application of this new standard in the future. At the current state of analysis, there is no information contrary to the disclosures in the Group's consolidated financial statements. Please refer to the disclosures made in Group financial statements for the full year of 2016.

The application of IFRS 16, Leases, is mandatory for periods from 2019 onwards. IFRS 16 introduces a standardized accounting model according to which leases are generally to be recognized on the lessee's balance sheet. A lessee recognizes a right-of-use asset representing its right to use a lease asset, as well as a liability resulting from the lease, which represents its obligation to make lease payments. There are exemptions for short-term leases and leases of low-value assets. Accounting for the lessor is comparable to that of the current standard; i.e., lessors continue to classify leases as financial or operating leases.

The Group has started to analyze the effects of this new standard and does not plan to apply the standard earlier than 2019. At the current stage of analysis, the Group plans to use the exemptions for short-term leases and leases of low-value assets and to recognize the corresponding lease payments as an expense generally on a straight-line basis over the particular lease term.

Application of IFRS 16 will likely lead to an increase in fixed assets and financial liabilities. Based on its present level of knowledge, the Group does not expect any significant impact overall on its key performance indicators, such as equity ratio or underlying EBITDA, however. For example, on the basis of the Group's future financial obligations in relation to operating leases as reported on December 31, 2016, the equity ratio would be reduced by about 1%.

With regard to all new changes described above, analysis of their impact has not yet been completed. The information provided above can be regarded as an update of the information provided in the last annual consolidated financial statements for the year ended December 31, 2016. Therefore, the information provided should be read in conjunction with the information disclosed in the Notes to those annual consolidated financial statements.

## 5. Business Acquisitions and Divestitures

### Acquisition of Essen BioScience

On March 24, 2017, the Group acquired the U.S. company Essen BioScience Inc. headquartered in Ann Arbor, Michigan, purchasing 100% of the voting rights in this company. The acquisition has been expanding the bioanalytics portfolio of the Lab Products & Services Division.

Essen BioScience develops and markets novel cell imaging and analysis systems for medical drug research, which are increasingly becoming standard equipment in pharmaceutical laboratories. These systems represent a platform of instrumentation, software and reagents for real-time live-cell imaging and fully automated data analysis. The information delivered by these systems provides new insight and understanding into the mechanisms of healthy and diseased cells, which helps significantly accelerate often time-consuming discovery and development of new drugs.

Founded in 1996, the company currently employs approximately 150 people and is expected to generate sales revenue of around U.S. \$60 million. Besides its headquarters in the USA, Essen BioScience has sales companies in the U.K. and in Japan.

Determination of the acquisition-date fair values of the assets acquired and liabilities assumed has not yet been completed. Therefore, the purchase price allocation is preliminary based on the current knowledge of management:

	Preliminary purchase price allocation € in mn
Other intangible assets	229.3
Property, plant and equipment	1.3
Inventories	9.1
Trade receivables	9.9
Other assets	0.7
Cash and cash equivalents	14.9
Deferred taxes - net	-73.3
Other liabilities	-22.1
<b>Net assets acquired</b>	<b>169.8</b>
Purchase price	309.4
<b>Goodwill</b>	<b>139.6</b>

The converted purchase price of €309.4 million was paid in cash. The expenses of €0.3 million directly attributable to the acquisition were recognized as other operating expenses. Goodwill is not expected to be tax-deductible. According to its present level of knowledge, the Group expects that the intangible assets to be recognized will be primarily technology-based, customer-related and brand-based.

Besides being attributable to the synergies that are to be realized by the acquiree's use of the Group's sales and distribution network, the resulting goodwill of the Umetrics acquisition is attributed to extension of the product portfolio of the Lab Products & Services Division and expansion of this division's position with respect to biopharmaceutical customers.

### Acquisition of Umetrics

On April 3, 2017, the Group acquired 100% of the voting rights in the Swedish company MKS Instruments AB (Umetrics) based in Umeå, Sweden. In the meantime, the company has been renamed "Sartorius Stedim Data Analytics AB." In addition to these shares, the Group acquired further related intangible assets through asset deals as part of the business combination. The acquisition adds complementary products to the portfolio of the Bioprocess Solutions Division.

Umetrics is a globally leading provider of data analytics software for modeling and optimizing biopharmaceutical development and manufacturing processes. The company currently employs approximately 50 people and is expected to generate sales revenue of about \$15 million in 2017.

The determination of the acquisition-date fair values of the assets acquired and liabilities assumed has not yet been completed. Therefore, the purchase price allocation is preliminary based on the current knowledge of management:

	<b>Preliminary purchase price allocation € in mn</b>
Other intangible assets	30.3
Property, plant and equipment	0.1
Inventories	0.0
Trade receivables	1.2
Other assets	0.3
Cash and cash equivalents	6.9
Deferred taxes - net	-6.3
Other liabilities	-4.6
<b>Net assets acquired</b>	<b>28.0</b>
Purchase price	75.0
<b>Goodwill</b>	<b>47.0</b>

The purchase price of approximately €75.0 million was paid in cash. The expenses €0.2 million directly attributable to the acquisition were recognized as other expenses in profit or loss. It is expected that the goodwill of this company will not be deductible for tax purposes. According to its present level of knowledge, the Group expects that the intangible assets recognized are primarily technology-based and customer-related intangible assets.

Since their initial consolidation, the entities acquired in the first half of 2017 have contributed sales revenue of around €16 million (Essen BioSicence) and €2 million (Umetrics) to consolidated earnings. On the whole, these figures did not have a material impact on Group earnings.

If the acquisitions had taken place as of January 1, 2017, sales revenue for the Group in the first half of 2017 would have been approximately €713.5 million. Without the impacts on the purchase price allocation, the effects on net profit would be immaterial.

## 6. Financial Instruments

### Carrying Amounts and Fair Values

€ in millions	Categories	June 30, 2017 Carrying amount	June 30, 2017 Fair value	Dec. 31, 2016 Carrying amount	Dec. 31, 2016 Fair value
Financial assets	Available for sale	5.7	5.7	3.8	3.8
Financial assets	Loans and receivables	3.3	3.3	3.2	3.2
Derivative financial instruments	Held for trading	0.0	0.0	0.3	0.3
Derivative financial instruments designated as hedging instruments	n/a	8.7	8.7	0.2	0.2
<b>Financial assets (non-current)</b>		<b>17.7</b>	<b>17.7</b>	<b>7.5</b>	<b>7.5</b>
<b>Trade receivables</b>	<b>Loans and receivables</b>	<b>271.6</b>	<b>271.6</b>	<b>241.2</b>	<b>241.2</b>
Receivables and other assets	Loans and receivables	23.5	23.5	14.7	14.7
Derivative financial instruments	Held for trading	0.1	0.1	0.0	0.0
Derivative financial instruments designated as hedging instruments	n/a	3.9	3.9	0.3	0.3
<b>Other financial assets (current)</b>		<b>27.4</b>	<b>27.4</b>	<b>15.0</b>	<b>15.0</b>
<b>Cash and cash equivalents</b>	<b>Loans and receivables</b>	<b>72.4</b>	<b>72.4</b>	<b>62.0</b>	<b>62.0</b>
<b>Loans and borrowings</b>	<b>Financial liabilities at cost</b>	<b>971.2</b>	<b>977.4</b>	<b>526.0</b>	<b>536.2</b>
<b>Finance lease liabilities</b>	<b>IAS 17</b>	<b>21.1</b>	<b>32.2</b>	<b>21.9</b>	<b>33.5</b>
Trade payables	Financial liabilities at cost	86.9	86.9	76.4	76.4
Trade payables   payments received for orders	n/a	40.6	40.6	44.0	44.0
<b>Trade payables</b>		<b>127.4</b>	<b>127.4</b>	<b>120.4</b>	<b>120.4</b>
Derivative financial instruments	Held for trading	6.2	6.2	5.6	5.6
Derivative financial instruments designated as hedging instruments	n/a	1.1	1.1	13.8	13.8
Other financial liabilities	Financial liabilities at cost	63.8	69.2	66.9	73.7
Other financial liabilities	Fair value through OCI	14.2	14.2	13.8	14.7
Other financial liabilities	Fair value through profit or loss	5.5	5.5	5.8	5.8
<b>Other financial liabilities</b>		<b>90.8</b>	<b>96.1</b>	<b>105.9</b>	<b>113.6</b>

For the equity investments measured at acquisition cost (financial assets), it is not possible to determine fair values reliably due to the absence of active markets. This applies mainly to shares in non-consolidated subsidiaries. These are essentially sales companies of the Group; the calculation of fair values for their activities would therefore not be relevant for the economic decisions of the users. There is currently no intention to sell the assets of Sartorius Group affiliates.

The fair values of the financial instruments were determined on the basis of the market information available on the reporting date and are to be allocated to one of the three levels of the fair value hierarchy in accordance with IFRS 13.

Level 1 financial instruments are calculated on the basis of prices quoted on active markets for identical assets and liabilities. In Level 2, financial instruments are calculated on the basis of input factors, which are derivable from observable market data or on the basis of market

prices for similar instruments. Level 3 financial instruments are calculated on the basis of input factors that cannot be derived from observable market data.

The financial instruments to be recognized at fair value on the reporting date are exclusively derivatives in the form of forward contracts, interest rate swaps and structured forward contracts. They were measured on the basis of their quoted exchange rates and market yield curves (Level 2).

The fair values to be disclosed for financial liabilities recognized at amortized cost, especially liabilities to banks and those related to note loans ("Schuldscheindarlehen"), as well as finance lease liabilities, were measured on the basis of the market interest rate curve, taking the current indicative credit spreads into account (Level 2).

The purchase price liability for the non-controlling interest in Sartorius Israel Ltd. and for the liability resulting from the AllPure phantom stock units are required to be disclosed in the amount of the present value of the expected purchase price payments. Their present value is to be derived in both cases from the expected revenues as of the exercise date and from the risk-adjusted discount rate (Level 3).

The fair values of the remaining financial assets and liabilities to be disclosed approximate the carrying amounts on account of their predominantly short-term maturity.

The maximum credit loss risk is reflected by the carrying amounts of the financial assets recognized in the Statement of Profit or Loss.

### Measurement of Fair Value

The Group recognizes transfers between the levels of the fair value hierarchies at the end of the reporting period during which the change has occurred. In the current reporting period, there were no transfers between the levels.

The valuation of the level 3 liability is based on a discounted cash flow technique in which the expected future payments that are discounted using a risk-adjusted discount rate are taken into account. The expected payments are determined by considering possible developments of future revenue and the amounts to be paid under each scenario. The significant unobservable input in this calculation is the future sales revenue which was considered at a com-

pound annual growth rate of 15-20% for the AllPure liability.

The carrying amount of this liability developed as follows:

	2017 € in mn	2016 € in mn
Balance at January 1	5.8	5.4
Financial expenses	0.1	0.0
Translation effects	-0.4	-0.1
<b>Balance at June 30</b>	<b>5.5</b>	<b>5.4</b>

An increase (a decrease) of the sales revenue by 10% in each of the following years would lead to an increase (a decrease) of the liability by €0.5 million (€0.5 million).

Concerning the liability for the purchase of the non-controlling interest in Sartorius Israel Ltd., the input factor that cannot be derived from observable market data is also sales growth for which a compound annual growth rate of approx. 15% was assumed.

The carrying amount of this liability developed as follows:

	2017 □ in mn	2016 € in mn
Balance at January 1	13.8	0.0
Initial measurement	0.0	13.4
Financial expenses	0.2	0.2
Translation effects	0.2	-0.1
Balance at June 30	14.2	13.5

An increase (a decrease) in expected sales revenue by 10% in each of the following years would lead to an increase (a decrease) of the liability by €1.4 million (€1.4 million).

## 7. Related Companies and Persons

The Group companies included in the consolidated financial statements carry out business activities and transactions in related party relationships as defined by IAS 24. In particular, this concerns transactions with non-consolidated subsidiaries and are generally concluded according to the customary market terms.

In the reporting period, sales revenue of €4.6 million (H1 2016: €4.2 million) was generated by these companies; there were liabilities from loans and borrow-

ings as well as trade payables, both totaling €11.9 million (H1 2016: €10.8 million). A long-term service contract exists with an affiliate for which expenses of €3.5 million (H1 2016: €3.1 million) were incurred in the reporting period.

For further details, also on related companies and persons, see page 159 in our 2016 Annual Report.

## **8. Other Disclosures**

In the interim reporting period, no asset impairments were identified. Generally, asset impairment tests need to be performed for goodwill and other assets with indefinite useful lives.

Regarding its acquisition activities, Sartorius placed a €350 million note loan in the first half of 2017 to further strengthen its financing structure.

The note loan consists of three tranches with maturity terms of 5, 7 and 10 years. These tranches completely bear fixed interest rates. In total, note loan tranches of €595 million are therefore outstanding as of June 30.

Exchange differences arising from net investments in foreign operations are recognized in other comprehensive income. In connection with the acquisitions in 2016 and 2017, these net investments increased significantly, which led to a respective impact on the Group's other comprehensive income.

In the reporting period, Sartorius AG paid dividends totaling €31.1 million, of which €15.4 million were for ordinary shares and €15.7 million for preference shares.

Independent, certified auditors performed an audit review of this consolidated six-month report. The figures of the individual second quarter in the statement of profit or loss, as well as the statement of comprehensive income, were not part of this review.

## **9. Material Events After the Reporting Date**

No material events occurred up to completion of the preparation of these interim financial statements.



# Independent Auditors' Review Report

## To Sartorius Aktiengesellschaft, Goettingen

We have reviewed the condensed interim consolidated financial statements of the Sartorius Aktiengesellschaft, Goettingen – comprising the condensed statement of profit or loss, statement of comprehensive income, statement of financial position, statement of cash flows, statement of the changes in equity and selected explanatory notes – together with the interim Group management report of the Sartorius Aktiengesellschaft, Goettingen, Germany, for the period from January 1 to June 30, 2017 that are part of the semi-annual financial report according to § 37 w WpHG ("Wertpapierhandelsgesetz": German Securities Trading Act). The preparation of the condensed interim consolidated financial statements in accordance with those IFRSs applicable to interim financial reporting as adopted by the EU, and of the interim Group management report in accordance with the requirements of WpHG applicable to interim Group management reports, is the responsibility of the company's management. Our responsibility is to issue a report on the condensed interim consolidated financial statements and on the interim Group management report based on our review.

We performed our review of the condensed interim consolidated financial statements and the interim Group management report in accordance with the German generally accepted standards for the review of financial statements established by the German Institute of Independent Auditors, "Institut der Wirtschaftsprüfer" (IDW). These standards require that we plan and perform the review to obtain reasonable assurance that the condensed interim consolidated financial statements have been prepared, in all material respects, in accordance with the IFRSs applicable to interim financial reporting, as adopted by the EU, and that the interim Group management report has been prepared, in all material respects, in accordance with WpHG requirements applicable to interim Group management reports. A review is limited primarily to company employees' responses to our inquiries and to analytical assessments and, therefore, does not provide the assurance attainable in a financial statement audit. Since, in accordance with our audit review assignment, we have not performed a full audit of the financial statements, we cannot issue an audit report.

Based on our review, no matters have come to our attention that cause us to presume that the condensed interim consolidated financial statements have not been prepared, in material respects, in accordance with the IFRSs applicable to interim financial reporting as adopted by the EU or that the interim Group management report has not been prepared, in material respects, in accordance with the requirements of WpHG applicable to interim Group management reports.

Hanover, Germany, July 20, 2017

KPMG AG  
Wirtschaftsprüfungsgesellschaft

Sven-Olaf Leitz  
Auditor

Frank Thiele  
Auditor

(German Public Auditor) (German Public Auditor)

# Responsibility Statement of the Legal Representatives

## **Declaration of the Executive Board**

We declare to the best of our knowledge that the condensed interim consolidated financial statements for the first half ended June 30, 2017, present a true and fair view of the actual net worth, financial situation and profitability of the Group in accordance with the accounting standards to be applied in preparing these statements. We also certify that the progress of the Group's business, including its business performance and its situation, are represented accurately in the Group interim report in all material respects and describe the most important opportunities and risks of the Group's projected development for the remaining six months of the financial year.

Goettingen, July 20, 2017

Sartorius AG

The Executive Board

## Contacts

Sartorius AG  
Weender Landstrasse 94–108  
37075 Goettingen, Germany

Phone +49.551.308.0  
Fax +49.551.308.3289  
www.sartorius.com

### Group Corporate Communications

Petra Kirchhoff  
Vice President  
Phone +49.551.308.1686  
petra.kirchhoff@sartorius.com

### Investor Relations

Andreas Theisen  
Director  
Phone +49.551.308.1668  
andreas.theisen@sartorius.com

## Financial Schedule

### August 29, 2017

Commerzbank Sector Conference Week |  
Frankfurt am Main, Germany

### September 6, 2017

Goldman Sachs European Medtech Conference |  
London, U.K.

### September 12, 2017

Morgan Stanley Global Healthcare Conference |  
New York, USA

### September 18–19, 2017

Berenberg German Corporate Conference |  
Munich, Germany

### October 24, 2017

Publication of nine-month figures for 2017

### November 28, 2017

German Equity Forum | Frankfurt am Main, Germany

### December 5, 2017

Berenberg European Conference | London, U.K.

### January 2018

Publication of preliminary results for fiscal 2017

### April 5, 2018

Annual General Shareholders' Meeting |  
Goettingen, Germany

### April 2018

Publication of first-quarter figures for 2018

This is a translation of the original German-language first-half Group interim financial report (January to June 2017) entitled "Sartorius Konzern Halbjahresbericht – Januar bis Juni 2017." Sartorius AG shall not assume any liability for the correctness of this translation. The original German interim report is the legally binding version. Furthermore, Sartorius AG reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

### Forward-looking Statements Contain Risks

This Sartorius Group Interim Report for the period from the beginning of January 2017 to the end of June 2017 contains various statements concerning the Sartorius Group's future performance. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually apply. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements.

Throughout the entire report, differences may be apparent as a result of rounding during addition.